Skin adverse reactions to Sars‐CoV‐2 vaccination: a relevant responsibility issue for dermatologists

Gisondi, Paolo; Bellinato, Francesco; Girolomoni, Giampiero

doi:10.1111/jdv.17854

Cited by 2 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the omalizumab group, only one patient (1.8%) described mild myalgia on the lower extremities after injection for 6 h. No adverse events were reported in the mepolizumab group [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye

Demir,

Tunakan Dalgic,

Mete Gokmen

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Real-life data on the efficacy of biologic agents (BAs) on asthma-comorbid CRSwNP are needed. Our primary goal is to investigate the effects of BAs on CRSwNP symptoms, as well as endoscopic and tomography scores. Our secondary goal is to show a reduction in the frequency of acute sinusitis exacerbations and the need for surgery. Materials and Methods: We conducted a multicenter, retrospective, real-life study. We screened the patients with asthma-comorbid CRSwNP treated with omalizumab or mepolizumab. A total of 69 patients (40 F/29 M; omalizumab n = 55, mepolizumab n = 14) were enrolled. We compared the visual analog scale (VAS), sinonasal outcome test-22 (SNOT-22), nasal congestion score (NCS), Lund–Mackay computed tomography score (LMS), and total endoscopic polyp scores (TPS) before and after BAs. We evaluated the endoscopic sinus surgery (ESS) and acute exacerbations of chronic rhinosinusitis (AECRS) frequencies separately, according to the BAs. Results: The overall median (min–max) age was 43 (21–69) years. The median (min–max) of biologic therapy duration was 35 (4–113) months for omalizumab and 13.5 (6–32) for mepolizumab. Significant improvements were seen in VAS, SNOT-22, and NCS with omalizumab and mepolizumab. A significant decrease was observed in TPS with omalizumab [95% CI: 0–4] (p < 0.001), but not with mepolizumab [95% CI: −0.5–2] (p = 0.335). The frequency of ESS and AECRS were significantly reduced with omalizumab [95% CI: 2–3] (p < 0.001) and [95% CI: 2–5] (p < 0.001); and mepolizumab [95% CI: 0–2] (p = 0.002) and [95% CI: 2–8.5] (p < 0.001), respectively. There was no significant difference in LMS with either of the BAs. Conclusions: Omalizumab and mepolizumab can provide a significant improvement in the sinonasal symptom scores. BAs are promising agents for CRSwNP patients with frequent exacerbations and multiple surgeries.

show abstract

“…In the omalizumab group, only one patient (1.8%) described mild myalgia on the lower extremities after injection for 6 h. No adverse events were reported in the mepolizumab group [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye

Demir,

Tunakan Dalgic,

Mete Gokmen

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Reaksi seperti "COVID arm" tidak berbahaya, dapat sembuh sendiri dan berbeda dengan reaksi hipersensitivitas tipe I, tidak menjadi kontraindikasi untuk vaksinasi lanjutan. 19 Baik infeksi maupun vaksin seringkali menyebabkan kekambuhan dari penyakit autoimun. Terdapat kemiripan secara genetik antara komponen protein spike SARS-COV-2 dengan protein pada manusia dan dapat terjadi reaksi silang dengan antigen pada manusia, disebut pula dengan mimikri molekular.…”

Section: Efek Samping Vaksin Covid-19 Pada Kulitunclassified

“…1.Reaksi lokal pada tempat injeksi Reaksi lokal pada tempat injeksi meliputi rasa nyeri (88%), kemerahan (20%), indurasi (25%), gatal (35%) dan bengkak (15%) yang timbul dalam kurun waktu 7 hari setelah vaksinasi, dan umumnya muncul beberapa menit hingga 2-3 hari paska vaksinasi. 19 Reaksi ini merupakan efek samping yang paling sering ditemukan paska vaksinasi COVID-19 (96%). Reaksi lokal pada lokasi injeksi rata-rata tidak berbahaya dan dapat sembuh sendiri dalam beberapa hari.…”

Section: Jenis Reaksi Efek Samping Paska Pemberian Vaksin Covid-19unclassified

A Cutaneous Adverse Effects in Covid-19 Vaccine

Nadeak

Gliselda

Budiyarto

et al. 2022

JKU

View full text Add to dashboard Cite

Pada Bulan Maret 2020, World Health Organization (WHO) mengumumkan Penyakit COVID-19 sebagaiPandemi. Vaksin adalah produk biologis yang dapat digunakan untuk menginduksi respon imun tubuh yang kemudian dapat memberikan perlindungan terhadap infeksi dan/atau penyakit pada paparan patogen, oleh karena itu, vaksinasimenjadi salah satu kunci pencegahan dan pemutusan rantai penyebaran COVID-19. Berdasarkan hasil uji klinis, vaksinCOVID-19 menunjukkan kadar imunogenisitas yang cukup menjanjikan dengan berbagai persentase efektivitas dantingkat keamanan yang cukup baik. Dengan dilaksanakannya vaksinasi di seluruh dunia, mulai bermunculan laporanefek samping derajat sedang hingga berat. Efek samping mukokutaneus penting untuk diperhatikan karena dapatterlihat secara kasat mata dan memiliki potensi menimbulkan rasa takut pada individu dan lingkungan sekitar, serta mengakibatkan keengganan masyarakat untuk melakukan vaksinasi.

show abstract

Skin adverse reactions to Sars‐CoV‐2 vaccination: a relevant responsibility issue for dermatologists

Abstract: Linked article: T. Gambichler et al. J Eur Acad Dermatol Venereol 2022; 36: 172–180. https://doi.org/10.1111/jdv.17744.

Cited by 2 publications

References 5 publications

The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye

The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye

A Cutaneous Adverse Effects in Covid-19 Vaccine

Contact Info

Product

Resources

About